Morning Overview on MSN
New prostate cancer immunotherapy cuts biomarkers by up to 99% in trial
A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...
A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...
Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results